Author
Listed:
- S. Intidhar Labidi-Galy
(Dana-Farber Cancer Institute and Harvard Medical School
Geneva University Hospitals)
- Eniko Papp
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Personal Genome Diagnostics)
- Dorothy Hallberg
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine)
- Noushin Niknafs
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Institute for Computational Medicine, Johns Hopkins University)
- Vilmos Adleff
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine)
- Michael Noe
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine)
- Rohit Bhattacharya
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Institute for Computational Medicine, Johns Hopkins University)
- Marian Novak
(Dana-Farber Cancer Institute and Harvard Medical School
Personal Genome Diagnostics)
- Siân Jones
(Personal Genome Diagnostics)
- Jillian Phallen
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine)
- Carolyn A. Hruban
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine)
- Michelle S. Hirsch
(Brigham and Women’s hospital and Harvard Medical School)
- Douglas I. Lin
(Brigham and Women’s hospital and Harvard Medical School
Beth Israel Deaconess Medical Center)
- Lauren Schwartz
(University of Pennsylvania Perelman School of Medicine)
- Cecile L. Maire
(Dana-Farber Cancer Institute and Harvard Medical School)
- Jean-Christophe Tille
(Division of Clinical Pathology, Faculty of Medicine, Geneva University Hospital)
- Michaela Bowden
(Brigham and Women’s hospital and Harvard Medical School)
- Ayse Ayhan
(Seirei Mikatahara Hospital
Hamamatsu University School of Medicine
Hiroshima University School of Medicine
Johns Hopkins University School of Medicine)
- Laura D. Wood
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine)
- Robert B. Scharpf
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine)
- Robert Kurman
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Johns Hopkins University School of Medicine)
- Tian-Li Wang
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Johns Hopkins University School of Medicine)
- Ie-Ming Shih
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Johns Hopkins University School of Medicine)
- Rachel Karchin
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine
Institute for Computational Medicine, Johns Hopkins University)
- Ronny Drapkin
(Dana-Farber Cancer Institute and Harvard Medical School
Brigham and Women’s hospital and Harvard Medical School
Penn Ovarian Cancer Research Center, University of Pennsylvania Perelman School of Medicine)
- Victor E. Velculescu
(Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine)
Abstract
High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian cancer and has a poor outcome. It has been proposed that fallopian tube cancers may be precursors of HGSOC but evolutionary evidence for this hypothesis has been limited. Here, we perform whole-exome sequence and copy number analyses of laser capture microdissected fallopian tube lesions (p53 signatures, serous tubal intraepithelial carcinomas (STICs), and fallopian tube carcinomas), ovarian cancers, and metastases from nine patients. The majority of tumor-specific alterations in ovarian cancers were present in STICs, including those affecting TP53, BRCA1, BRCA2 or PTEN. Evolutionary analyses reveal that p53 signatures and STICs are precursors of ovarian carcinoma and identify a window of 7 years between development of a STIC and initiation of ovarian carcinoma, with metastases following rapidly thereafter. Our results provide insights into the etiology of ovarian cancer and have implications for prevention, early detection and therapeutic intervention of this disease.
Suggested Citation
S. Intidhar Labidi-Galy & Eniko Papp & Dorothy Hallberg & Noushin Niknafs & Vilmos Adleff & Michael Noe & Rohit Bhattacharya & Marian Novak & Siân Jones & Jillian Phallen & Carolyn A. Hruban & Michell, 2017.
"High grade serous ovarian carcinomas originate in the fallopian tube,"
Nature Communications, Nature, vol. 8(1), pages 1-11, December.
Handle:
RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-00962-1
DOI: 10.1038/s41467-017-00962-1
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Elena Denisenko & Leanne Kock & Adeline Tan & Aaron B. Beasley & Maria Beilin & Matthew E. Jones & Rui Hou & Dáithí Ó Muirí & Sanela Bilic & G. Raj K. A. Mohan & Stuart Salfinger & Simon Fox & Khaing , 2024.
"Spatial transcriptomics reveals discrete tumour microenvironments and autocrine loops within ovarian cancer subclones,"
Nature Communications, Nature, vol. 15(1), pages 1-15, December.
- Philip Smith & Thomas Bradley & Lena Morrill Gavarró & Teodora Goranova & Darren P. Ennis & Hasan B. Mirza & Dilrini Silva & Anna M. Piskorz & Carolin M. Sauer & Sarwah Al-Khalidi & Ionut-Gabriel Funi, 2023.
"The copy number and mutational landscape of recurrent ovarian high-grade serous carcinoma,"
Nature Communications, Nature, vol. 14(1), pages 1-15, December.
- Liana Goehring & Sarah Keegan & Sudipta Lahiri & Wenxin Xia & Michael Kong & Judit Jimenez-Sainz & Dipika Gupta & Ronny Drapkin & Ryan B. Jensen & Duncan J. Smith & Eli Rothenberg & David Fenyö & Tony, 2024.
"Dormant origin firing promotes head-on transcription-replication conflicts at transcription termination sites in response to BRCA2 deficiency,"
Nature Communications, Nature, vol. 15(1), pages 1-18, December.
- Jennifer B. Shah & Dana Pueschl & Bradley Wubbenhorst & Mengyao Fan & John Pluta & Kurt D’Andrea & Anna P. Hubert & Jake S. Shilan & Wenting Zhou & Adam A. Kraya & Alba Llop Guevara & Catherine Ruan &, 2022.
"Analysis of matched primary and recurrent BRCA1/2 mutation-associated tumors identifies recurrence-specific drivers,"
Nature Communications, Nature, vol. 13(1), pages 1-19, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-017-00962-1. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.